Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3541-3560 of 3,900 trials

Autoimmune Diseases: VIS171 Treatment

We are testing a new treatment called VIS171 for individuals with autoimmune diseases. The study aims to evaluate its safety and how the body reacts to it.

Alopecia AreataSystemic Lupus ErythematosusImmune-Mediated Focal Segmental Glomerulosclerosis1-2 yearsSafety phase (I)Infectious DiseasesInternal Medicine

Colorectal Cancer: Galunisertib and Capecitabine Study

We are investigating a new drug combination for patients with advanced colorectal cancer that hasn't responded to chemotherapy. The goal is to learn more about its safety and effectiveness in treating this condition.

Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Colorectal Cancer: FOLFIRI and Cetuximab Treatment

We are studying whether a combination of FOLFIRI and Cetuximab is effective for patients with advanced colorectal cancer who have specific genetic markers. This research aims to improve first-line treatment options for these patients.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

X-ALD: Pramipexole for Leg Symptoms

We are investigating whether pramipexole can help reduce restless leg symptoms in women with X-linked Adrenoleukodystrophy. This study aims to improve their sleep and walking performance.

X-linked AdrenoleukodystrophyRestless Legs Syndrome3-6 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurology

Advanced Clear-Cell Renal Carcinoma: Digital Monitoring with Cabozantinib and Nivolumab

We are studying how digital tracking of symptoms can help adjust treatments for patients with advanced clear-cell renal carcinoma receiving Cabozantinib and Nivolumab. This may improve their overall health and quality of life during treatment.

Kidney Cancer>2 yearsMonitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncologyUrology

Ulcerative Colitis: Comparing Risankizumab and Vedolizumab

We are studying whether risankizumab is more effective and safe than vedolizumab for adults with moderate to severe ulcerative colitis who have not yet received targeted treatments.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Hypertension and Obesity: Orforglipron Study

We are investigating a new medication, Orforglipron, for people with hypertension who are also overweight or obese. The goal is to see if it can safely help manage their blood pressure.

High Blood Pressure1-2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Locally Advanced Rectal Cancer: NeoAspMet Trial

We are studying whether adding aspirin or metformin to standard chemotherapy improves tumor response in patients with locally advanced rectal cancer. This trial aims to see if these treatments can lead to better outcomes compared to standard care.

Locally Advanced Rectal CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: PM534 Treatment

We are testing a new drug called PM534 for patients with advanced solid tumors. The goal is to learn about its safety and how it may help in treating this condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Systemic Lupus Erythematosus: AZD5492 Study

We are investigating a new medication for adults with systemic lupus erythematosus or idiopathic inflammatory myopathies. The study focuses on its safety and how the body processes the drug.

Systemic Lupus ErythematosusIdiopathic Inflammatory Myopathy>2 yearsSafety phase (I)Rheumatology

Dry Age-Related Macular Degeneration: PST-611 Treatment

We are testing the safety and tolerability of PST-611 in individuals with dry age-related macular degeneration. This study aims to understand how well the treatment is accepted by patients.

Dry Age-Related Macular Degeneration6-12 monthsSafety phase (I)Ophthalmology

Pleural Mesothelioma: Ivonescimab Treatment Study

We are evaluating ivonescimab for patients with relapsing pleural mesothelioma who have already been treated with immunotherapy and chemotherapy. The study aims to assess its safety and effectiveness as a potential new treatment option.

Pleural Mesothelioma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Heart Failure: Ferric Derisomaltose Treatment

We are studying whether ferric derisomaltose can improve heart health and reduce hospitalizations in people with iron deficiency and chronic heart failure. This trial compares it to no intravenous iron treatment.

Chronic Heart Failure1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Chronic Hepatitis Delta: Brelovitug Treatment Study

We are studying a new medication, brelovitug, for people with chronic hepatitis delta infection. The trial aims to see if it works better than waiting for treatment and to evaluate its safety.

Hepatitis D>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatology

Basal Cell Carcinoma: Electrochemotherapy vs. Radiotherapy

We are comparing a new treatment called electrochemotherapy with standard radiotherapy for small basal cell carcinomas. The study will also assess side effects, appearance after treatment, and patient satisfaction.

Basal Cell Carcinoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesDermatologyOncology

Gastric Cancer: Pre-operative Treatment with Capecitabine and Atezolizumab

We are studying a combination of chemotherapy and immunotherapy for patients with resectable gastric and GE-junction cancer. The goal is to see if this treatment is safe and effective in shrinking tumors before surgery.

Gastric Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

TryptoBPH: Tryptophan for Benign Prostatic Hyperplasia

We are studying whether tryptophan can improve urinary symptoms in men with benign prostatic hyperplasia. The trial will also look at its effects on prostate size and quality of life.

Benign Prostatic Hyperplasia6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineUrology

Atopic Dermatitis: Investigational Compounds Study

We are evaluating new treatments for moderate to severe atopic dermatitis to see if they improve skin symptoms better than a placebo. The study also looks at the safety of these treatments.

Atopic Dermatitis3-6 monthsEfficacy phase (II)Investigational MedicinesAllergologyDermatology

Neuroblastoma: Innovative Stem Cell Transplant and Immunotherapy

We are studying a new stem cell transplant method followed by immunotherapy for children with relapsed or resistant high-risk neuroblastoma. This trial aims to evaluate the safety and effectiveness of this approach in improving treatment outcomes.

Neuroblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Felzartamab for Kidney Transplant Recipients with Late Antibody-Mediated Rejection

We are studying whether felzartamab can improve outcomes for kidney transplant recipients facing late antibody-mediated rejection. This trial compares the new treatment to a placebo to assess its effectiveness and safety.

Kidney Transplant Rejection1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNephrology